Had a fundamental role in the registration strategy and post-registration development of cisplatin and oxaliplatin
Positions at Memorial Sloan Kettering Cancer Center (NY), Columbia Presbyterian (NY), Hospital St. Louis (Paris),
Instituto Mario Negri (Milan) and Institut Gustave Roussy (Villejuif)
David P. Nowotnik, Ph.D., Senior Vice President Research and Development
Senior Director, Product Development, Guilford Pharmaceuticals, Inc.
Group Leader, Bristol-Myers Squibb.
Section Leader, Amersham International.
Research Chemist, Tate and Lyle and Aspro-Nicholas.
PhD, Organic Chemistry, University of London.
Stephen B. Thompson, Vice President and CFO
Controller and Administration Manager, API.
Controller, Robert E. Woolley, Inc., a hotel real estate company.
Controller, OKC Limited Partnership, an oil and gas company.
Accounting and finance, Santa Fe International Corporation.
Phillip Wise, Vice President Business Development and Strategy
VP, Commercial and Business Development
and Chief Financial Officer, Enhance Pharmaceuticals.
VP, Commercial and Business Development, Ardent Pharmaceuticals.
Director of Managed Care Marketing & Director of New Product
Planning, Glaxo Wellcome.
MBA, University of Virginia.
BS, Industrial and Systems Engineering, Georgia Institute of Technology.
Frank Jacobucci, Vice President of Sales and Marketing
Over 20 years experience in sales management.
Senior sales executive positions at oncology-focused companies including MGI Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services.